Syntara secures positive FDA review and 52-week data boost for amsulostat

An announcement from Syntara Limited ( (AU:SNT) ) is now available.

Syntara Limited has reported positive top-line 52-week data from a Phase 2 blood cancer trial of its lead candidate amsulostat, noting safety and tolerability alongside growing clinical benefit beyond 24 weeks that compares favorably with other drugs in development. Supported by significant non-dilutive grant funding and past success in licensing and capital raising, the company positions these results as a key near-term value driver that could strengthen its competitive standing in oncology and enhance prospects for future partnerships and commercialization.

The favorable FDA review of Syntara’s Phase 2b trial plan for amsulostat, combined with its financial runway through 2027, suggests the company is well placed to advance clinical programs without immediate dilution. For investors and other stakeholders, the convergence of positive safety and efficacy signals, a robust patent portfolio and multiple ongoing studies provides several potential catalysts over the next 12 to 18 months.

The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.

More about Syntara Limited

Syntara Limited is an Australian-founded clinical-stage drug developer focused on first-in-class and best-in-class therapies, underpinned by an in-house long-life patent portfolio. The company targets blood cancer indications, is backed by specialist healthcare investors with 44% institutional ownership, and is funded through 2027 with multiple Phase 2, Phase 1 and preclinical assets aimed at markets exceeding $4.5 billion.

Average Trading Volume: 837,016

Technical Sentiment Signal: Sell

Current Market Cap: A$52.3M

For an in-depth examination of SNT stock, go to TipRanks’ Overview page.